| abstract |
THEY REFER TO COMPOUNDS OF FORMULA (I), WHERE "T" IS OF PREFERENCE Cl; R25 IS - (CH2) n-C6H4-R24, WHERE R24 IS ORTO, GOAL OR STOPS WITH RESPECT TO (CH2) n, WHERE n IS 1; two; 3; 4 or 5; BEING R25 SELECTED FROM -CONH- (CH2) 3-Ph, -CONH- (CH2) 2-CH- (CH3) 2, -CONH- (CH2) 2-COO-CH3, -CONH-CH2-COO-CH2CH3, -CONH- (CH2) 2-COOH, -CONH-CH2-COOH, -CONH (CH3) -CH2-CO-N (CH3) 2 O -CONH-CH2-Ph. IT ALSO REFERS TO THE INTERMEDIATE COMPOUND OF FORMULA (II). FORMULA (I) COMPOUNDS ACT AS INHIBITORS OF MATRIX METALOPROTEASES (MMP) THAT POSSESS BETTER BIOAVAILABILITY AND BIOLOGICAL STABILITY, BEING USEFUL TO: (a) MITIGATE THE EFFECTS OF OSTEOARTHRITIS OR ARTHRIES REUMATE (b) DELAYING THE METASTASIS OF TUMORS OR THE DEGENERATIVE LOSS OF CARTILAGE AFTER A TRAUMATIC ARTICULAR INJURY; (c) REDUCE CORONARY THROMBOSIS; OR (d) PRACTICE BIRTH CONTROL |